Related Experiment Video
Updated: Nov 16, 2025

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Cost-utility analysis of an integrated genetic/epigenetic test for assessing risk for coronary heart disease
Younsoo Jung1, David Frisvold2, Timur Dogan1
1Cardio Diagnostics Inc., Coralville, IA 52241, USA.
Abstract:
Aim: New epigenetically based methods for assessing risk for coronary heart disease may be more sensitive but are generally more costly than current methods. To understand their potential impact on healthcare spending, we conducted a cost-utility analysis. Methods: We compared costs using the new Epi + Gen CHD™ test with those of existing tests using a cohort Markov simulation model. Results: We found that use of the new test was associated with both better survival and highly competitive negative incremental cost-effectiveness ratios ranging from -$42,000 to -$8000 per quality-adjusted life year for models with and without a secondary test. Conclusion: The new integrated genetic/epigenetic test will save money and lives under most real-world scenarios. Similar advantages may be seen for other epigenetic tests.
Related Concept Videos
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures

